newsfilter
← Latest News
GlobeNewswire·

Helus Pharma to Participate in the Guggenheim Healthcare Innovation Conference

  • Helus Pharma CEO Michael Halstead will participate in a fireside chat at the Guggenheim Healthcare Innovation Conference in Boston.
  • The event will webcast live on Monday, November 9, 2026, at 3:00 p.m. EDT.
  • A replay of the webcast will be available on Helus Pharma's investor relations website.
  • Helus Pharma is a clinical-stage company developing novel serotonergic agonists (NSAs) to address mental health conditions like depression & anxiety.
  • The company's lead drug HLP003 is in Phase 3 clinical development for major depressive disorder & holds Breakthrough Therapy Designation from the FDA.
  • HLP004, another proprietary NSA, is currently in Phase 2 clinical development for generalized anxiety disorder.
  • Helus Pharma operates in Canada, the United States, the United Kingdom, & Ireland.
  • The news release includes standard forward-looking statements regarding future business objectives & product development plans.
  • The U.S. FDA, Health Canada, & other regulatory authorities have not evaluated claims regarding the efficacy of Helus Pharma's proposed products.
  • Investor & media contact details for Matthew Beck, Greg Cavers, & Charlotte Wray are provided for further inquiries.